湿性年龄相关性黄斑变性眼切换至布罗鲁单抗后注射间隔延长的相关因素
基于美国IRIS注册库的回顾性观察性队列研究,纳入2015只眼(1890例患者)从其他抗VEGF药物切换至仅布罗鲁单抗治疗至少12个月。58.9%的眼为间隔延长者。切换前注射间隔较短与间隔延长显著正相关(调整OR 5.6,95%CI 4.5-6.9,P<0.001),结论认为切换前治疗间隔长度是与成功延长间隔最强相关的特征。
要点
- 切换前注射间隔<8周 vs ≥8周,间隔延长的调整OR为5.6(95%CI 4.5-6.9,P<0.001)。
- 2015只眼中1186只(58.9%)在12个月时达到间隔延长且视力稳定或改善。
- 指数注射视力40-65字母的眼较视力更高类别眼显著更不可能成为间隔延长者。
核心结论
- 切换前治疗间隔长度是与布罗鲁单抗成功延长注射间隔最强相关的特征。
- 需要更频繁注射(即切换前间隔较短)的治疗经验患者切换至布罗鲁单抗后间隔延长幅度最大。
- 作者认为,在仔细权衡获益与风险后,布罗鲁单抗可能因需频繁注射而治疗负担较高的患者的有价值选择。
研究设计与样本
- 回顾性、观察性队列研究。
- 研究对象为美国IRIS注册库中2019年10月8日至2021年11月26日期间从其他抗VEGF药物切换至仅布罗鲁单抗治疗≥12个月的成人新生血管性年龄相关性黄斑变性(nAMD)患者。
- 共纳入1890例患者的2015只眼。
- 采用单变量和多变量分析检验人口学与临床特征与切换后间隔延长可能性的关联。
主要发现
- 2015只眼中1186只(58.9%)为间隔延长者。
- 单变量分析中,除间隔延长者切换前间隔较非延长者短外(均值5.9±2.1周 vs 10.1±7.6周),两组人口学与临床特征相当。
- 多变量logistic回归模型中,切换前间隔<8周 vs ≥8周与布罗鲁单抗治疗间隔延长显著正相关(调整OR 5.6,95%CI 4.5-6.9,P<0.001)。
- 指数注射视力为40-65字母的眼较指数视力更高(更好)类别的眼显著更不可能成为间隔延长者。
关键数值与推荐
- 间隔延长者定义为:12个月时布罗鲁单抗注射间隔较切换前间隔(末次已知既往抗VEGF注射与首次[指数]布罗鲁单抗注射之间的时间)延长≥2周,且12个月视力较指数注射时稳定(获得或丢失<10字母)或改善(获得≥10字母)。
- 非间隔延长者为不满足上述标准的眼。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate factors associated with anti-vascular endothelial growth factor (VEGF) injection interval extension in patients with neovascular age-related macular degeneration (nAMD) switched to brolucizumab treatment. DESIGN: Retrospective, observational cohort study. PARTICIPANTS: Adults in the United States-based IRIS® Registry (Intelligent Research in Sight) with nAMD who switched from another anti-VEGF agent to brolucizumab-only treatment for ≥ 12 months from October 8, 2019, through November 26, 2021. METHODS: Univariable and multivariable analyses examined associations of demographic and clinical characteristics with the likelihood of interval extension after switching to brolucizumab therapy. MAIN OUTCOME MEASURES: Eyes were classified as either extenders or nonextenders at 12 months. Extenders were eyes that achieved (1) an extension of ≥ 2 weeks in the brolucizumab injection interval at 12 months versus the interval before switching (time between the last known prior anti-VEGF injection and first [index] brolucizumab injection) and (2) stable (< 10 letters gained or lost) or improved (≥ 10 letters gained) visual acuity (VA) at 12 months versus VA at index injection. RESULTS: Of 2015 eyes among 1890 patients who switched to brolucizumab treatment, 1186 (58.9%) were extenders. In univariable analyses, demographic and clinical characteristics were comparable between extenders and nonextenders, except that extenders had shorter intervals before switching versus nonextenders (mean, 5.9 ± 2.1 weeks vs. 10.1 ± 7.6 weeks, respectively). In multivariable logistic regression modeling, a shorter interval before switching was associated significantly and positively with interval extension with brolucizumab therapy (adjusted odds ratio, 5.6 for interval before switching of < 8 weeks versus ≥ 8 weeks; 95% confidence interval, 4.5-6.9; P < 0.001), and eyes with an index VA of 40 to 65 letters were significantly less likely to be extenders than eyes in the higher (better) index VA categories. CONCLUSIONS: Length of the treatment interval before switching was the characteristic associated most strongly with successful interval extension with brolucizumab. Treatment-experienced patients who required more frequent injections (i.e., shorter intervals before switching) showed the greatest extensions when switching to brolucizumab. With careful consideration of benefits and risks, brolucizumab may be a valuable option for patients with higher treatment burdens because of the need for frequent injections. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- MacCumber MW, Wykoff CC, Karcher H, et al. Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab. Ophthalmology. 2023. PMID: 36990322. doi:10.1016/j.ophtha.2023.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。